Companies: 10,795·Total market cap: $144.5T
Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc.

DNANYSEHealthcare● Active
$8.23
+$0.01(+0.12%)
Market Cap$537620602
P/E Ratio
52W High$17.58
52W Low$5.37
Overview

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

dna · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 11 Wall Street analysts in the past 3 months

SellBuy

Buy

11 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
5
Hold
2
Sell
4
Strong Sell
0
Total: 11 · Buy rate: 45.5%

12-Month Price Target

High

$12.00

Consensus

$7.84

-4.6% upside

Low

$4.35

Median: $7.5 · Last Close: $8.22

The Ginkgo Bioworks Holdings, Inc. (DNA) analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month DNA price target is $7.84, representing -4.6% upside from the current price of $8.22.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $8 (-4.6%)

Consensus Target

$7.84

-4.6% upside

High Target

$12

46.0%

Low Target

$4.35

-47.1%

Current Price

$8.22

as of today

Based on analyst price targets, the DNA stock price prediction for the next 12 months ranges from $4.35 to $12. The consensus DNA price forecast of $7.84 implies -4.6% upside from the current price of $8.22.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$8.493.30%

1-day model range: $8.4–$8.58. Peak: $8.58 (+3.30%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$4-50.0%
2028$3-63.8%
2029$3-69.2%
2030$2-71.8%
2031-73.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BEARISH

Based on 14 technical indicators

21%8%71%
3Buy
1Neutral
10Sell
RSI (14)55.4Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · DNA · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$8.89SELL
MA 10$8.91SELL
MA 20$8.49SELL
MA 50$8.01BUY
MA 100$8.20BUY
MA 200$9.55SELL
Current $DNA · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$8.75SELL
EMA 10$8.76SELL
EMA 20$8.63SELL
EMA 50$8.33SELL
EMA 100$8.44SELL
EMA 200$9.21SELL
Current $DNA · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
BTIG2026-03-12
Maintains
SellSell
TD Cowen2026-01-08
Maintains
BuyBuy
BTIG2025-08-25
Maintains
SellSell
TD Cowen2024-09-20
Maintains
BuyBuy
BTIG2024-08-23
Maintains
SellSell
Goldman Sachs2024-07-09
Maintains
SellSell
BTIG2024-06-26
Maintains
SellSell
BTIG2024-05-15
Downgrade ↓
NeutralSell
Morgan Stanley2024-05-15
Maintains
Equal WeightEqual Weight
William Blair2024-05-10
Downgrade ↓
Market PerformUnderperform

Wall Street analysts have recently issued updated ratings on Ginkgo Bioworks Holdings, Inc. (DNA) stock. Of the recent 33 rating actions, 0 were upgrades and 8 were downgrades. 11 analysts currently cover DNA.

Analyst Recommendation Trends

Buy ratings00
Hold ratings00
Sell ratings11

DNA analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$174M

↑ 32.8% YoY

Revenue Next Year

$123M

↓ 29.2% YoY

EPS This Year

$-5.64

EPS Next Year

$-4.33

↓ 23.3% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast DNA EPS of $-5.64 for the current fiscal year, based on estimates from 1 analysts. The DNA revenue forecast is $174M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The DNA stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus DNA price target is $7.84 (-4.6% upside), with an analyst consensus of Buy.

The DNA short-term stock prediction for tomorrow is $8.49 (+3.30%). The DNA stock price prediction for 2027 estimates an average of $4. The DNA stock prediction for 2030 projects a range of $2–$3.

Ginkgo Bioworks Holdings, Inc. trades on NYSE under the ticker DNA. The DNA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 45% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

DNA forecast · 8 questions

According to 11 Wall Street analysts, the average 12-month DNA price target is $7.84, with a high forecast of $12.00 and a low of $4.35. The median price target is shown in the chart above when available. This implies -4.6% potential upside from the current price of $8.22.

DNA price targetWhat is DNA price targetDNA analyst price targetDNA 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.